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Introduction: Carboplatin/paclitaxel chemotherapy with bevaci-
zumab is an accepted standard treatment for advanced nonsquamous
non-small cell lung cancer (NSCLC). The development of nanopar-
ticle albumin-bound paclitaxel (nab-paclitaxel) has circumvented
many of the infusion difficulties associated with standard solvent-
based paclitaxel (in Cremophor) and offers theoretical advantages in
efficacy. This trial evaluated the combination of nab-paclitaxel,
carboplatin, and bevacizumab in advanced (stage IIIB/IV) nonsqua-
mous NSCLC.
Methods: Fifty patients with stage IIIB/IV NSCLC were enrolled
between October 2005 and April 2006; 48 were treated with nab-
paclitaxel 300 mg/m2, carboplatin area under the curve  6, and
bevacizumab 15 mg/kg every 21 days until progression or intoler-
able toxicity, up to 4 cycles; an additional 2 cycles could be
administered to responding patients and the physician’s discretion;
maintenance bevacizumab was not administered. Patient demo-
graphics included: 56% female, median age 67 years (range, 32–83),
performance status 0 (52%) or 1 (48%), adenocarcinoma 86%, and
stage IV disease 82%. Responding patients received a minimum of
4 cycles. The primary end point was response rate.
Results: Response rate was 31% with a stable disease rate of 54%.
No complete responses were observed. Median progression-free
survival was 9.8 months (range,1–22.3), and median survival was
16.8 months. Most frequent grades 3 and 4 treatment-related toxic-
ities were neutropenia (54%) and fatigue (17%).
Conclusions: The combination of nab-paclitaxel, carboplatin, and
bevacizumab was well tolerated with moderate neutropenia. Ad-
verse events were manageable. Survival results are encouraging.
These results indicate that this combination has promising activity as
first-line therapy in patients with nonsquamous NSCLC.
Key Words: Paclitaxel, Platinum, Monoclonal, Multicenter,
Metastatic.
(J Thorac Oncol. 2009;4: 1537–1543)
Platinum-based doublet chemotherapy is the standard ini-tial treatment for advanced non-small cell lung cancer
(NSCLC). Although chemotherapy improves quality of life
(QOL) and survival in advanced NSCLC, progression-free
survival (PFS) is 6 months, and overall survival is approx-
imately 1 year with response rates of 20%.1,2 Many currently
used standard doublet chemotherapy regimens in advanced
NSCLC share similar outcomes.1 Eastern Cooperative Oncol-
ogy Group (ECOG) 4599 evaluated the addition of bevaci-
zumab to standard carboplatin/paclitaxel chemotherapy in
nonsquamous NSCLC.3 Entry criteria for ECOG 4599 have
become standard for the use of bevacizumab in NSCLC and
included nonsquamous histology, absence of brain metastasis
or history of hemoptysis, and exclusion of patients on anti-
coagulation. Bevacizumab improved PFS (6.2 months versus
4.5 months, p  0.001) and overall survival (12.3 months
versus 10.3 months, p  0.003) but increased the risk of
bleeding complications, even in carefully selected patients
(4.4% versus 0.7%, p  0.001). In ECOG 4599,4 patients
continued maintenance bevacizumab until progression of
disease. ECOG 4599 established bevacizumab in the treat-
ment of advanced nonsquamous NSCLC, although the Euro-
pean AVAiL trial,4 while demonstrating an improvement in
PFS, failed to show a survival benefit for the addition of
bevacizumab to gemcitabine/cisplatin chemotherapy in
NSCLC.
Paclitaxel originally isolated from the bark of the Pa-
cific yew (Taxus brevifolia) is one of the most widely used
chemotherapeutic agents, demonstrating activity in a variety
of tumor types. The standard formulation of paclitaxel (sP)
consists of paclitaxel dissolved in a proprietary solvent,
Cremophor EL (BASF Corp, Aktiengellschaft, Germany) and
ethanol. In addition to its poor water solubility, sP has a
number of other limitations: sP administration requires rou-
tine premedication with corticosteroids, diphenhydramine,
and H2 antagonists to reduce the incidence of potentially
life-threatening hypersensitivity caused by a response to the
formulation vehicle, Cremophor. Also, sP must be adminis-
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tered over a period of 3 hours and requires the use of
specialized non-DEHP containing infusion sets and in-line
filters.5
Nanoparticle albumin-bound paclitaxel (nab-paclitaxel,
Abraxane, Abraxis BioScience, Los Angeles, CA), a unique
protein formulation of paclitaxel, was developed to reduce
the toxicities associated with paclitaxel and the Cremophor/
ethanol vehicle while maintaining or improving the chemo-
therapeutic effect of the drug. Preclinical studies have sug-
gested that this formulation may improve drug delivery into
tumor.6,7 In phase I trials, the maximum tolerated dose of
nab-paclitaxel was higher than the labeled dose for paclitaxel
and the Cremophor/ethanol vehicle.8 In phase II trials, anti-
tumor activity was documented in metastatic breast can-
cer.9,10 A phase III testing of nab-paclitaxel in advanced
breast cancer demonstrated significantly higher efficacy for
nab-paclitaxel versus paclitaxel and the Cremophor/ethanol
vehicle as measured by overall response rates (33% versus
19%, p  0.001) and time to tumor progression (5.8 months
versus 4.2 months, p  0.006).11 nab-Paclitaxel has been
evaluated in NSCLC. Rizvi et al.12 reported promising single
agent results of weekly nab-paclitaxel with a response rate of
30%, time to progression of 5 months, and overall survival of
11 months in patients with advanced NSCLC. Green et al.13
reported a response rate of 16% with nab-paclitaxel given as
a single agent every 3 weeks in advanced NSCLC with a
median survival of 11 months. nab-Paclitaxel has been eval-
uated in combination with carboplatin in the treatment of
NSCLC utilizing both the weekly14 and every 3-week15
schedule of nab-paclitaxel. This phase II study was designed
to evaluate the safety and antitumor activity of nab-paclitaxel
combined with carboplatin and bevacizumab every 21 days in
patients with advanced stage IIIB/IV NSCLC.
PATIENTS AND METHODS
Patients
Eligible patients had histologically or cytologically
confirmed advanced stage IIIB (wet)/IV nonsquamous
NSCLC with evidence of inoperable local recurrence or
metastasis and had measurable disease by RECIST.16 Patients
could not have received previous chemotherapy for advanced
disease but could have received previous radiation as long as
the measurable disease was outside the radiation field or had
progressed since completion of radiation. Other entry criteria
included an ECOG performance status (PS) 0–1, age 18
years, and adequate hematologic, hepatic, and renal function.
Exclusion criteria included pregnancy or breast feeding, pre-
existing peripheral neuropathy of National Cancer Institute
grade 1, significant renal disease or proteinuria, active
cardiac disease, history of seizure disorder, or another active
malignancy. In addition, there were extensive exclusion stan-
dard criteria related to the administration of bevacizumab,
similar to those used in ECOG 4599 study,3 including the
presence of central nervous system metastases, gross hemop-
tysis (1/2 tsp of red blood), unstable angina, or the use of
therapeutic anticoagulation. All patients signed an informed
consent.
Study Design
This was an open-label, single arm phase II study. The
protocol was approved by a central Institutional Review
Board with jurisdiction over specific sites that registered
patients on study.
Patients received intravenous nab-paclitaxel 300 mg/m2,
carboplatin intravenous (mg/mL min) area under the curve 
6, and bevacizumab 15 mg/kg on day 1 of each 21-day cycle.
Patients did not receive maintenance bevacizumab after che-
motherapy.
Patients were to receive a minimum of 4 cycles of
treatment; however, patients who progressed or who devel-
oped an intolerable toxicity were taken off treatment. At the
discretion of the treating physician, patients who achieved a
complete response (CR) or partial response (PR) could re-
ceive an additional 2 cycles to a maximum of 6 cycles.
Responses were evaluated between days 14 and 21 of cycles
2 and 4 (and 6 if applicable). Any additional treatment was at
the discretion of the treating physician.
Therapy could continue in the absence of disease pro-
gression and unacceptable toxicity. All patients who received
at least one dose of nab-paclitaxel, carboplatin, and bevaci-
zumab were evaluable for response and toxicity.
Assessments
Verification that patients satisfied inclusion and exclu-
sion criteria, review and signing of the informed consent, and
a medical history were completed at baseline. A physical
examination including vital signs, height and weight, assess-
ment of the ECOG PS, complete blood count with differential
and platelet count, disease assessment, and laboratory tests
(total bilirubin, serum creatinine, aspartate transaminase, ala-
nine transaminase, alkaline phosphatase, and serum calcium),
and pregnancy test (when indicated) were also done at base-
line. Toxicity was assessed at each patient visit and for 30
days after the last dose. Radiologic assessment of disease
status was done every 6 weeks. Follow-up visit occurred at
3-month intervals for 2 years (measured from the start of
treatment) to collect survival data and information about any
additional therapy.
Response and progression were evaluated using the
standardized international criteria proposed by the RECIST
committee.16
Adverse events (AEs) were recorded throughout the
trial. Toxicities and AEs were graded using the Common
Terminology Criteria for Adverse Events Version 3.0.17 The
relationship of each event to treatment was assessed by the
treating physician and recorded. Additional information
about each event, such as treatment required, eventual out-
come, and whether or not therapy had to be interrupted or
dosages reduced, was also collected. AEs were recorded for
up to 30 days following the last study treatment.
Statistical Analysis
The primary objective of this study was to determine
antitumor activity of nab-paclitaxel/carboplatin/bevacizumab
in patients with advanced NSCLC, based on RECIST crite-
ria.16 The secondary objectives of this study were to evaluate
time to disease progression, determine the duration of re-
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sponses to nab-paclitaxel/carboplatin/bevacizumab in pa-
tients with advanced NSCLC, evaluate the safety of nab-
paclitaxel/carboplatin/bevacizumab in this patient population,
evaluate 1- and 2-year survival, determine the proportion of
patients with stable disease (SD) 16 weeks, and to evaluate
changes in QOL using Functional Assessment of Cancer
Therapy (FACT)-Taxane questionnaires.18
Based on an assumed objective response rate of 25%
(improvement from 11%, based on ECOG 159419) and a
sample size of 49 patients (including an additional 10% for
early dropout), the 95% confidence interval, calculated using
the exact binomial method, for the objective (complete or
partial) target lesion response rate was projected to be 13 to
37%. It should be noted, however, that ECOG 1594 included
all histologies of NSCLC and PS 2 patients, a somewhat
different population than that studied here.
Overall response rate was analyzed using descriptive
methods (frequency counts and proportions of response
CRs  PRs). The median and range of both the time to
response and duration of response and SD 16 weeks were
measured. Patient baseline characteristics and disease factors
were summarized using descriptive statistics. The incidence
and type of treatment-related AEs were tabulated and sum-
marized for grades 3–4 events.
Kaplan-Meier techniques20 in SAS (SAS Institute,
Cary, NC) were used on the intent-to-treat population to
estimate times-to-event end points such as the time to PFS
and survival. Point probabilities every 3 months were calcu-
lated, and survival curves were generated using Statistica
software, version 6.1, 2003 (Statsoft, Inc., Tulsa, OK). For
the calculation of survival, and for patients who died during
treatment, the last contact date was used in place of a missing
death date. Subsequently, the date of last dose of treatment
was used in place of a missing last contact date.
TABLE 1. Patient Characteristics at Baseline
Number and Percentage
of Patients
Number of patients enrolled 50
Sex
Female 28 (56)
Male 22 (48)
Race
White 40 (80)
Black 5 (10)
Asian 4 (8)
Hispanic 1 (2)
Age (yr)
Median (range) 67 (32–83)
ECOG performance status
0 26 (52)
1 24 (48)
Histology
Adenocarcinoma 43 (86)
Bronchioalveolar 1 (2)
Large cell 4 (8)
NOS 2 (4)
Prior treatment
Surgery 19 (30)
Radiation 4 (8)
Most frequent sites of metastasisa
Adrenals 6 (12)
Bone 14 (28)
Liver 14 (28)
Lung 12 (24)
Lymph nodes 14 (28)
Mediastinal nodes 4 (8)
Pleura 7 (14)
Pleural effusion 7 (14)
Other 5 (10)
Number of metastatic sites per patient
1 19 (38)
2 15 (30)
3 9 (18)
4 1 (2)
a Patients may have had more than one site of metastasis.
ECOG, Eastern Cooperative Oncology Group; NOS, not otherwise specified.
TABLE 2. Best Response After Treatment and Reasons for
Nonevaluability and Study Discontinuation
Number and Percentage
of Patients
Total number enrolled 50
Total number treated 48
Evaluable patients 43 (90)
Best response (n  48)
PR 15 (31.3)
SD 26 (54.2)
SD 6 mo (n  11)
SD 6 mo (n  15)
PD 2 (4.2)
NE 5 (10.4)
CBR (CR  PR SD 6 mo) 26 (54.2)
Reason for nonevaluability
Discontinued in cycle 1 4
No baseline tumor measurement entered 1
Reason for discontinuation (N  50)
Normal study completion 17 (34.0)
Adverse eventa 16 (32.0)
Investigator request 1 (2.0)
Progressive disease 11 (22.0)
Withdrew consent or refused treatment 5 (10.0)
Total patients surviving 20 (40.0)
Cause of death (n  30)
Progressive disease 26 (86.7)
COPD 1 (3.3)
Pulmonary embolus 1 (3.3)
Pulmonary hemorrhage 1 (3.3)
Suicide 1 (3.3)
AEs included pulmonary embolism (n  3), neuropathy (n  2) and n  1 each for
hypotension, rectal fistula, skin necrosis, febrile neutropenia, fatigue, fatigue with
neuropathy, pulmonary disorder, GI perforation, and unconfirmed event (most likely
pneumonia).
PR, partial response; SD, stable disease; CR, complete response; CBR, clinical
benefit rate; COPD, chronic obstructive pulmonary disease; NE, nonevaluable.
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RESULTS
Patient Characteristics
A total of 50 patients were registered on the trial.
Patient demographics at baseline are summarized in Table 1.
Two patients who enrolled were not treated; one patient
withdrew consent before treatment and the other was found to
have brain metastases and therefore was ineligible.
Treatment Outcomes
Responses are summarized in Table 2. This study
produced no CRs. The overall response rate was 31%, and the
clinical benefit rate (CR PR [SD6 months]) was 54%.
The median time to response was 1.3 months (range, 1.2–
2.6), and the median duration of response was 8.9 months
(range, 2.9–19.1). Overall survival, PFS, and time to progres-
sion results, including medians and details at 3, 6, 9, 12, 15,
18, and 21 months, are summarized in Figures 1 (A & B) and 2,
respectively. Survival at 1- and 2- years was 62% and 30%,
respectively.
Drug Delivery
The median number of cycles completed, for all 3
drugs, was 4 (range, 1–6). Nineteen patients received 5 or 6
cycles as they had good responses at the end of cycle 4.
The mean dose intensities of all 3 drugs were nab-
paclitaxel 98.1%, carboplatin 97.1%, and bevacizumab
99.1%. The percentage of patients who had any study drug
doses delayed or reduced was 37.5%. These dosing modifi-
cations were largely attributed to toxicity, specifically neu-
ropathy, fatigue, neutropenia, and thrombocytopenia.
Toxicity
Although treatment could be delayed for up to 3 weeks
to allow for recovery from adverse events, 34% of patients
discontinued study treatment due to adverse events. Most
treatment-related toxicities were mild to moderate in severity.
Very few grade 4 toxicities were reported, with the exception
of neutropenia, which occurred in 18 patients (37.5%). One
fatal pulmonary hemorrhage was reported. Toxicities occur-
ring in more than one patient are summarized in Table 3.
Grades 3–4 toxicities limited to one patient included epi-
staxis, dehydration, dyspnea, facial edema (grade 4), pulmo-
nary embolus (grade 4), hemoptysis, hyperkalemia, infection,
macular rash, mucositis, nausea, orthostatic hypotension,
FIGURE 1. Overall and progression-free survival.
FIGURE 2. Time to progression.
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pain, gastrointestinal perforation, sepsis, deep vein thrombo-
sis vomiting, and generalized weakness. Twenty-seven pa-
tients (56%) experienced alopecia: five patients (10%) grade
1 and 22 patients (46%) grade 2. The incidence of grade 3
peripheral neuropathy was relatively low (2% grade 3 and 0%
grade 4) and there was no obvious, unexpected exacerbation
of myelosuppression; grades 3–4 neutropenia were expected
and occurred in 26 patients (54%; grade 3, 17% and grade 4,
37%). One patient died of complications associated with
chronic obstructive pulmonary disease unrelated to study
treatment.
Quality of Life
QOL was assessed using the FACT-Taxane scale.18
Over the course of the study (cycles 1–4 and additional
cycles 5 and 6), QOL decreased significantly with the excep-
tion of emotional well-being. Emotional well-being increased
throughout cycles 1–5 and was significantly higher than
baseline at cycle 3 (p 0.05). Changes at cycles 5 and 6 were
interpreted with care as patient numbers completing the
survey at these timepoints, and at the end of treatment and
follow-up, were limited. QOL is summarized graphically by
subscale in Figure 3.
DISCUSSION
This study of nab-paclitaxel, carboplatin, and bevaci-
zumab in patients with nonsquamous NSCLC produced PRs
in 31% of patients; disease was stabilized in 54% of patients
with 6 months duration in 11 patients (26%). Although the
response rate was somewhat lower than expected, the sur-
vival results were encouraging and compare favorably with
previous reports. However, the proportion of female patients
in this trial was unusually high and may account for some of
this favorable outcome.
ECOG 45993 established the role of bevacizumab in the
treatment of nonsquamous NSCLC with modest improve-
ments in median progression-free and overall survival. How-
ever, an EORTC trial of gemcitabine/cisplatin chemotherapy
alone versus the same chemotherapy in combination with
bevacizumab failed to show a survival benefit for the bevaci-
zumab arm.21 ECOG 4599 placed patients on maintenance
bevacizumab after completion of chemotherapy. In this trial,
patients did not receive maintenance bevacizumab (this de-
cision was made primarily for practical reasons as this trial
was largely conceived and conducted before US Food and
Drug Administration approval of bevacizumab for NSCLC).
No prospective trials have addressed the benefit of mainte-
nance bevacizumab in the treatment of advanced NSCLC,
and this remains an important unanswered question.
Several studies suggest bevacizumab may improve che-
motherapy administration into tumor by normalization of
tumor vasculature.22,23 nab-Paclitaxel may offer improved
drug delivery into tumor as well. Several preclinical studies
have suggested more efficient delivery of paclitaxel into
TABLE 3. Grades 3–4 Treatment-Related Adverse Events,
More Than One Patient
Total number of patients enrolled 50
Total number of patients treated 48
Body System: Adverse Events Grade 3 Grade 4 Total Percentage
Hematologic
Leukopenia 2 0 2 (4.2)
Neutropenia 8 18 26 (54.2)
Thrombocytopenia 4 1 5 (10.4)
Nonhematologic
Anorexia 2 0 2 (4.2)
Constipation 3 0 3 (6.3)
Diarrhea 2 0 2 (4.2)
Fatigue 6 2 8 (16.7)
Febrile neutropenia 3 2 5 (10.4)
Neuropathy 5 0 5 (10.4)
Peripheral neuropathy 2 0 2 (4.2)
FIGURE 3. Quality of life.
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tumor cells with albumin-bound formulation of paclitaxel
compared with solvent-based paclitaxel. Albumin is trans-
ported across capillary walls by caveolin-1, which is acti-
vated by gp60 oligomerization on capillary endothelium.24
This mechanism seems to improve transport of nab-paclitaxel
as well. Once in the tumor interstitium, nab-paclitaxel uptake
by tumor cells is enhanced by binding to secreted protein,
acidic and rich in cysteine.25,26 Interestingly, higher expres-
sion of caveolin-1 and secreted protein, acidic and rich in
cysteine by tumors correlates with more aggressive behavior,
suggesting nab-paclitaxel may be particularly efficacious in
those tumors.26–31
The results of this trial are promising and merit further
exploration. Although the response rate in this multicenter
phase II study was similar to that previously reported for
combination therapy for advanced NSCLC,12 the PFS and
overall survival results were higher than previously reported
in patients with advanced NSCLC. After completion of this
study, 54% of patients went on to receive second-line ther-
apy; 14% received pemetrexed, 8% received docetaxel, 6%
received paclitaxel, and 6% received the combination of
carboplatin and paclitaxel. Subsequent trials have suggested
that pemetrexed is particularly active in nonsquamous
NSCLC,32 and that may have contributed to the positive
overall survival results observed in this trial. However, the
prolonged PFS observed supports that some of the benefit
was likely derived from the combination therapy used in
this trial.33
In this study, toxicity was generally acceptable. The
low incidence of grade 3 peripheral neuropathy and the
absence of any obvious exacerbation of chemotherapy-in-
duced myelosuppression by the addition of bevacizumab to
this regimen are particularly noteworthy. Phase III evaluation
of this combination would determine whether it is truly more
efficacious than previous regimens. The optimal dosing
schedule of nab-paclitaxel (weekly versus q 21 day) and the
role of maintenance bevacizumab are important issues that
should be addressed.
APPENDIX
The following medical oncologists from USOR net-
work institutions also participated in this study: MB Berger,
Ocala, FL; T Cartwright, Ocala, FL; DA Richards, Tyler, TX;
P Acevedo, Hudson, NY; JC Andersen, Portland, OR; JH
Bordelon, Ft. Worth, TX; GM Custer, Overland Park, KS; NJ
Di Bella, Aurora, CO; MT Gall, Burnsville, MN; LE Garbo,
Albany, NY; TL Goodman, Schenectady, NY; D Gruenberg,
Portland, OR; S Hinton, Kansas City, MO; WJ Hyman, Tyler,
TX; CE Kampe, Austin, TX; M Kasper, Austin, TX; E Kent,
Overland Park, KS; RN Kerr, Dallas, TX; AD Kritz, Raleigh,
NC; S Kruger, Hampton, VA; ME Lee, Norfolk, VA; DM
Loesch, Indianapolis, IN; R Marsh, Manassas, VA; PL Mo-
ran, Boulder, CO; M Neubauer, Overland Park, KS; FW
Nugent, Albany, NY; R Reid, Fairfax, VA; SR Rousey,
Edina, MN; J Sandbach, Austin, TX; MA Savin, Dallas, TX;
DQ Vu, Albany, NY; JA Wangsness, Maplewood, MN; and
S Witta, Lakewood, CO.
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